CUTISS, a Swiss biotech company specializing in regenerative medicine, has closed a CHF 56 million Series C funding round, bringing its total capital raised to over CHF 125 million. The funding will support the continued development and commercialization of denovoSkin, a personalized, bioengineered skin graft designed for patients undergoing surgery for burns, reconstruction, or plastic procedures.
The company is currently conducting a Phase 3 clinical trial for denovoSkin across Switzerland and eight EU member states. This trial is focused on adolescent and adult patients with severe burns, and the first data set is expected by the end of 2026. denovoSkin has already received Orphan Drug Designation from Swissmedic, the European Medicines Agency, and the U.S. FDA, which provides regulatory advantages and extended market exclusivity.
In addition to clinical development, CUTISS is scaling up its manufacturing capabilities through a fully automated platform that enables decentralized, cost-effective production of personalized tissue therapies. This platform is designed to support large-scale rollout and improve access to denovoSkin globally.
The company also plans to launch VitiCell, a CE-marked medical device for skin re-pigmentation in patients with vitiligo. Developed by IBSA Pharma, VitiCell allows autologous cell grafting and may complement denovoSkin treatments in the future. CUTISS holds exclusive global commercialization rights and will bring the product to market once EU MDR certification is granted.
As part of its expansion strategy, CUTISS has signed a collaboration agreement with Rode Kruis Ziekenhuis (RKZ), a leading European burn center and clinical trials partner. This agreement lays the groundwork for CUTISS’s first international commercial production facility in the Netherlands, pending regulatory approval of denovoSkin.
The Series C round was co-led by long-standing investor Giammaria Giuliani’s family office and a U.S. family represented by Shiloh Advisors AG. New investors included industry players, family offices, and Swisspreneur, an investor collective supporting Swiss innovation.
CUTISS was launched in 2017 as a spin-off from the University of Zurich’s Tissue Biology Research Unit. With its focus on personalized skin regeneration and scalable tissue engineering, the company is positioning itself as a leader in next-generation therapeutic solutions.
KEY QUOTES:
“The successful closing and partnerships demonstrates confidence in our vision and ability to bring transformative skin therapies to patients. We’re grateful for the continued trust of existing investors and warmly welcome new investors on board, including key strategic ones.”
“The agreement with RKZ sets the stage for our future expansion with the potential to revolutionize the skin surgery market in Europe and globally.”
Dr. Daniela Marino, CEO and co-founder of CUTISS
“As a clinical institution dedicated to advancing burn care, we’re committed to support CUTISS and the development of denovoSkin. We’re excited to continue our closer collaboration, and the agreement we’ve signed sets out our vision for bringing their revolutionary skin tissue therapy to our patients as a priority.”
Nadine Vieleers, CEO Rode Kruis Ziekenhuis / Burn Center Beverwijk
“We’re proud that Swisspreneur participated in the latest funding round of CUTISS, a pioneering Swiss biotech company. Their mission to revolutionize skin regeneration is exactly the kind of bold innovation we love to support, and we’re excited for the next phase in the journey ahead.”
Silvan Krähenbühl, speaking on behalf of Swisspreneur
“Our ongoing partnership with CUTISS to industrialize skin tissue therapy highlights our commitment to advancing automation in high-growth areas such as cell biology and personalized medicine. Tecan’s expertise and technologies deliver precision and reproducibility at scale, enabling customers to transform research breakthroughs into real-world solutions to improve people’s lives and health.”
Monica Manotas, Tecan CEO
